β-adrenergic antagonists influence abdominal aorta contractility by mechanisms not involving β-adrenergic receptors

Folia Biologica
|November 19, 2014
PubMed

Insights

Beta-adrenergic receptor (β-AR) inhibitors like propranolol and SR59230A show additional actions beyond blocking β-receptors. These compounds may act as alpha-adrenergic receptor (α-AR) antagonists in rabbit aorta, influencing vascular function.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology

Background:

  • Beta-adrenergic receptors (β-AR) are crucial for cardiovascular function.
  • Beta-blockers primarily target cardiac β-receptors but may have other effects.
  • Investigating novel mechanisms of β-AR inhibitors is important for understanding their pleiotropic actions.

Purpose of the Study:

  • To explore additional mechanisms of β-AR inhibitors in rabbit abdominal aorta.
  • To investigate the effects of β-AR inhibitors on α-adrenergic receptors and calcium influx.
  • To evaluate the actions of propranolol, betaxolol, metoprolol, and SR59230A.

Main Methods:

  • Responses of phenylephrine and PGF(2α) precontracted rabbit aortic rings to β-AR inhibitors were assessed.
  • The effect of propranolol on phenylephrine concentration-contraction curves was examined.
  • The influence of α-AR blockade (phentolamine) and calcium channel blockade (verapamil) on propranolol's action was studied.

Main Results:

  • Propranolol and SR59230A induced relaxation in phenylephrine-precontracted rings, unlike betaxolol and metoprolol.
  • β-AR inhibitors caused contraction with PGF(2α), except SR59230A which caused relaxation at higher concentrations.
  • Propranolol shifted the phenylephrine curve rightward, suggesting competitive antagonism at α1-ARs.
  • Phentolamine reduced propranolol's maximal contraction, while verapamil enhanced it.

Conclusions:

  • SR59230A and propranolol likely act as competitive α1-AR antagonists in rabbit aortic rings.
  • Propranolol exhibits weak relaxation via Ca2+ channel inactivation after α-AR blockade.
  • SR59230A has an additional, unelucidated mechanism of action at high concentrations in the rabbit aorta.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.3K